{"hands_on_practices": [{"introduction": "Asteatotic dermatitis frequently occurs in older adults who may have comorbidities such as chronic venous insufficiency, creating a complex clinical picture. Distinguishing skin changes originating from epidermal barrier dysfunction versus those driven by underlying venous hypertension is a fundamental diagnostic challenge. This exercise will hone your ability to construct a differential diagnosis by systematically integrating clinical morphology, patient history, and objective findings from venous duplex ultrasonography [@problem_id:4413755].", "problem": "A patient aged $72$ years presents in mid-winter with intense pruritus and painful fissures on the anterolateral shins. The fissures form a polygonal, “dry riverbed” pattern and bleed minimally when the skin is flexed. The medial ankle (“gaiter”) region shows brown hyperpigmentation, ill-defined scaly eczematous plaques, and $1+$ pitting edema. There is a history of long-standing varicose veins. The environment is heated and dry. Venous duplex ultrasound (VDU) demonstrates great saphenous vein reflux at the mid-calf with a valve closure time of $0.9\\,\\mathrm{s}$, an incompetent perforator with reflux of $0.7\\,\\mathrm{s}$, and deep venous segments with closure times all $1.0\\,\\mathrm{s}$ (competent). No arterial disease is suspected, and dorsalis pedis pulses are palpable.\n\nConstruct a diagnostic flow that distinguishes asteatotic dermatitis (eczema craquelé) with fissuring from coexisting stasis dermatitis by integrating the observed skin signs and VDU findings. Your flow must be justified from first principles of skin barrier physiology and venous hemodynamics, using the following foundations without shortcuts:\n\n- Barrier function depends on stratum corneum lipids and ambient humidity; increased transepidermal water loss (TEWL) correlates with xerosis and fissuring.\n- Venous hypertension arises from valvular incompetence and increases capillary hydrostatic pressure, driving edema and red blood cell extravasation via Starling forces.\n- Pathologic superficial venous reflux is defined as $0.5\\,\\mathrm{s}$, deep venous reflux as $1.0\\,\\mathrm{s}$, and perforator incompetence commonly as $0.35\\,\\mathrm{s}$ to $0.5\\,\\mathrm{s}$.\n\nWhich option best describes a logically valid, stepwise diagnostic flow for this patient, correctly classifying asteatotic dermatitis versus stasis dermatitis and identifying their potential coexistence?\n\nA. Start with morphology and distribution: if polygonal fissures on anterolateral shins with minimal erythema occur in a low-humidity setting, infer barrier failure leading to asteatotic dermatitis; then query gaiter signs (hyperpigmentation, edema) and confirm venous hypertension by VDU thresholds (superficial reflux $0.5\\,\\mathrm{s}$ and perforator reflux $0.35\\,\\mathrm{s}$ to $0.5\\,\\mathrm{s}$, deep veins $\\leq 1.0\\,\\mathrm{s}$). Diagnose coexistence if both the craquelé pattern and gaiter stasis signs are present with pathologic superficial/perforator reflux. If only craquelé signs and no pathologic reflux, diagnose isolated asteatotic dermatitis; if gaiter stasis signs with pathologic reflux predominate, diagnose stasis dermatitis.\n\nB. Begin with fissuring: fissures indicate stasis dermatitis if any venous signal is present on VDU, regardless of reflux duration or distribution. If fissuring is absent, diagnose asteatotic dermatitis; VDU thresholds are unnecessary.\n\nC. Use ankle-brachial index (ABI) as the primary discriminator: ABI $0.9$ indicates stasis dermatitis and ABI $0.9$ indicates asteatotic dermatitis; duplex reflux thresholds are secondary and only confirm disease severity.\n\nD. Prioritize biophysical measurement: classify as asteatotic dermatitis if TEWL is elevated, regardless of skin distribution, and classify as stasis dermatitis only if lipodermatosclerosis is palpable and superficial reflux exceeds $2.0\\,\\mathrm{s}$. Coexistence cannot be diagnosed unless a venous ulcer is present.\n\nE. Start with duplex: if any incompetent perforator is found but deep veins remain competent, classify the entire limb as stasis dermatitis, even if only polygonal fissures are present without gaiter hyperpigmentation or edema. If perforators are competent but hyperpigmentation and edema are present, classify as asteatotic dermatitis.", "solution": "The problem statement is analyzed for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Patient Data**: Age $72$ years; presents in mid-winter; intense pruritus; painful fissures on anterolateral shins.\n- **Morphology**: Fissures in a polygonal, “dry riverbed” pattern with minimal bleeding. Medial ankle (“gaiter”) region shows brown hyperpigmentation, ill-defined scaly eczematous plaques, and $1+$ pitting edema.\n- **History and Context**: Long-standing varicose veins; heated and dry environment.\n- **Vascular Assessment**:\n  - Venous Duplex Ultrasound (VDU): Great saphenous vein (GSV) reflux with valve closure time of $0.9\\,\\mathrm{s}$; incompetent perforator with reflux of $0.7\\,\\mathrm{s}$; deep venous segments competent with closure times all $1.0\\,\\mathrm{s}$.\n  - Arterial: No arterial disease suspected; dorsalis pedis pulses palpable.\n- **Foundational Principles for Reasoning**:\n  1. Skin barrier function depends on stratum corneum lipids and humidity. Increased transepidermal water loss (TEWL) is linked to xerosis and fissuring.\n  2. Venous hypertension from valvular incompetence increases capillary hydrostatic pressure, leading to edema and red blood cell (RBC) extravasation (via Starling forces).\n  3. Pathologic reflux thresholds: superficial vein $0.5\\,\\mathrm{s}$; deep vein $1.0\\,\\mathrm{s}$; perforator vein $0.35\\,\\mathrm{s}$ to $0.5\\,\\mathrm{s}$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Groundedness**: The problem is scientifically sound. The clinical presentation is a classic example of coexisting asteatotic dermatitis and stasis dermatitis, common in the elderly. The pathophysiology described for both conditions (barrier dysfunction for asteatotic dermatitis, venous hypertension for stasis dermatitis) is correct. The VDU findings and the provided thresholds for pathology are standard in clinical practice. The entire scenario is medically realistic and based on established principles of dermatology and vascular medicine.\n- **Well-Posedness**: The problem is well-posed. It provides sufficient clinical and instrumental data to arrive at a conclusive diagnosis. The question asks for a logical diagnostic flow, which can be constructed uniquely from the provided principles and data.\n- **Objectivity**: The problem uses precise, objective medical terminology and quantitative data (reflux times). It is free from subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is a well-constructed clinical reasoning problem that is scientifically accurate, complete, and objective. A solution will be derived.\n\n### Derivation of Diagnostic Flow\n\nA robust diagnostic process integrates clinical findings with underlying pathophysiology, confirmed by appropriate investigations.\n\n1.  **Clinical Assessment (Morphology and Distribution)**: The process must begin with a careful clinical examination. The patient presents with two distinct clinical patterns in two different, classic locations.\n    *   **Anterolateral Shins**: The \"polygonal, 'dry riverbed' pattern\" (eczema craquelé) of fissures is the hallmark of asteatotic dermatitis. This condition is driven by xerosis (dry skin) resulting from impaired stratum corneum barrier function. The patient's age ($72$), the winter season, and the dry, heated environment are all significant risk factors that promote increased TEWL, consistent with Principle 1.\n    *   **Medial Ankle (Gaiter Region)**: The combination of brown hyperpigmentation (hemosiderin deposition from RBC extravasation), pitting edema, and eczematous plaques is the cardinal triad of stasis dermatitis. This pattern is pathognomonic for chronic venous insufficiency (CVI).\n\n2.  **Pathophysiological Correlation and Hypothesis Formulation**: Based on the clinical assessment, two distinct pathophysiological processes are hypothesized.\n    *   The shin findings suggest barrier dysfunction leading to asteatotic dermatitis.\n    *   The gaiter region findings suggest venous hypertension leading to stasis dermatitis (Principle 2).\n    *   The presence of both patterns strongly suggests the **coexistence** of the two conditions.\n\n3.  **Confirmatory Testing**: A hypothesis of stasis dermatitis must be confirmed by objectively demonstrating underlying venous hypertension.\n    *   The VDU is the gold standard test for this purpose.\n    *   Applying the thresholds from Principle 3 to the patient's VDU results:\n        *   GSV (superficial vein) reflux of $0.9\\,\\mathrm{s}$ is pathologic, as $0.9\\,\\mathrm{s}  0.5\\,\\mathrm{s}$.\n        *   Perforator vein reflux of $0.7\\,\\mathrm{s}$ is pathologic, as $0.7\\,\\mathrm{s}  0.5\\,\\mathrm{s}$.\n        *   Deep veins are competent ($1.0\\,\\mathrm{s}$).\n    *   The VDU findings confirm the presence of significant superficial and perforator venous incompetence, providing the hemodynamic basis for the observed stasis changes.\n\n4.  **Synthesis and Final Diagnosis**: The diagnostic flow integrates all data points. The clinical pattern of xerosis and craquelé on the shins, exacerbated by environmental factors, establishes the diagnosis of asteatotic dermatitis. The clinical pattern of edema and hyperpigmentation in the gaiter area, coupled with VDU-confirmed pathologic venous reflux, establishes the diagnosis of stasis dermatitis. Therefore, the correct conclusion is that the patient has coexisting asteatotic dermatitis and stasis dermatitis.\n\nThe correct diagnostic flow is: (1) Identify patterns by morphology/distribution to form hypotheses (asteatotic vs. stasis). (2) Use VDU to confirm or refute the venous hypertension hypothesis. (3) Synthesize findings to diagnose isolated conditions or their coexistence.\n\n### Option-by-Option Analysis\n\n**A. Start with morphology and distribution: if polygonal fissures on anterolateral shins with minimal erythema occur in a low-humidity setting, infer barrier failure leading to asteatotic dermatitis; then query gaiter signs (hyperpigmentation, edema) and confirm venous hypertension by VDU thresholds (superficial reflux $0.5\\,\\mathrm{s}$ and perforator reflux $0.35\\,\\mathrm{s}$ to $0.5\\,\\mathrm{s}$, deep veins $\\leq 1.0\\,\\mathrm{s}$). Diagnose coexistence if both the craquelé pattern and gaiter stasis signs are present with pathologic superficial/perforator reflux. If only craquelé signs and no pathologic reflux, diagnose isolated asteatotic dermatitis; if gaiter stasis signs with pathologic reflux predominate, diagnose stasis dermatitis.**\n- This option perfectly matches the derived logical flow. It starts with clinical examination, correctly links findings to pathophysiology, uses the VDU for confirmation with the correct thresholds, and correctly outlines the criteria for diagnosing coexistence or isolated conditions.\n- **Verdict: Correct.**\n\n**B. Begin with fissuring: fissures indicate stasis dermatitis if any venous signal is present on VDU, regardless of reflux duration or distribution. If fissuring is absent, diagnose asteatotic dermatitis; VDU thresholds are unnecessary.**\n- This option is incorrect. Fissuring is the defining feature of eczema craquelé (asteatotic dermatitis). It also incorrectly dismisses the importance of quantitative reflux duration, which is fundamental to diagnosing venous incompetence. Stating that the absence of fissuring implies asteatotic dermatitis is a logical contradiction.\n- **Verdict: Incorrect.**\n\n**C. Use ankle-brachial index (ABI) as the primary discriminator: ABI $0.9$ indicates stasis dermatitis and ABI $0.9$ indicates asteatotic dermatitis; duplex reflux thresholds are secondary and only confirm disease severity.**\n- This option is fundamentally flawed. The ABI assesses **arterial** circulation, not venous. Stasis dermatitis is a **venous** disease. Confusing arterial and venous pathologies is a critical error. The VDU is the primary diagnostic tool for the cause of stasis dermatitis, not a secondary test for severity.\n- **Verdict: Incorrect.**\n\n**D. Prioritize biophysical measurement: classify as asteatotic dermatitis if TEWL is elevated, regardless of skin distribution, and classify as stasis dermatitis only if lipodermatosclerosis is palpable and superficial reflux exceeds $2.0\\,\\mathrm{s}$. Coexistence cannot be diagnosed unless a venous ulcer is present.**\n- This option sets arbitrary and incorrect criteria. Diagnosis cannot be made \"regardless of distribution.\" The reflux threshold of $2.0\\,\\mathrm{s}$ is incorrect; the problem specifies $0.5\\,\\mathrm{s}$. Requiring lipodermatosclerosis or a venous ulcer for diagnosis ignores earlier stages of the diseases. Coexistence is clearly present in this case without an ulcer.\n- **Verdict: Incorrect.**\n\n**E. Start with duplex: if any incompetent perforator is found but deep veins remain competent, classify the entire limb as stasis dermatitis, even if only polygonal fissures are present without gaiter hyperpigmentation or edema. If perforators are competent but hyperpigmentation and edema are present, classify as asteatotic dermatitis.**\n- This option contains reversed logic. It incorrectly subordinates the clinical picture to the VDU findings and makes erroneous conclusions. Classifying classic asteatotic dermatitis as stasis dermatitis based solely on a VDU finding is an error. Furthermore, labeling hyperpigmentation and edema (hallmarks of stasis) as asteatotic dermatitis is a direct contradiction of established pathophysiology.\n- **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4413755"}, {"introduction": "The cornerstone of managing asteatotic dermatitis is the aggressive restoration of the stratum corneum's barrier function through consistent emollient use. To ensure therapeutic success, clinicians must translate the qualitative advice of \"moisturize liberally\" into a quantitative prescription. This practice problem focuses on calculating the precise amount of emollient a patient needs for a defined treatment period, a practical skill essential for effective prescribing and patient education [@problem_id:4413712].", "problem": "An adult with asteatotic dermatitis (eczema craquelé) exhibits impaired stratum corneum barrier function with increased transepidermal water loss (TEWL). To restore the lipid barrier, a clinician prescribes a full-body emollient regimen specified by an areal dose density of $2\\,\\mathrm{g}/\\mathrm{m}^{2}$ per application. The adult’s body surface area is $1.7\\,\\mathrm{m}^{2}$. The regimen requires uniform full-body application $4$ times per day over $7$ consecutive days. Assume no loss due to wastage, evaporation, or clothing transfer, and that dose density is uniformly achieved over the entire body surface at each application. Starting from the definition that the mass applied per application equals the areal dose density multiplied by the treated area, determine the total emollient mass required to dispense for one week. Express your final answer in grams, and round your answer to three significant figures.", "solution": "The problem statement is first subjected to a rigorous validation process.\n\n**Step 1: Extract Givens**\n-   Areal dose density, $\\sigma$: $2\\,\\mathrm{g}/\\mathrm{m}^{2}$ per application\n-   Adult's body surface area, $A$: $1.7\\,\\mathrm{m}^{2}$\n-   Application frequency, $f$: $4$ times per day\n-   Treatment duration, $T$: $7$ consecutive days\n-   Assumption: No loss of emollient.\n-   Assumption: Uniform full-body application is achieved.\n-   Governing relation: Mass applied per application equals the areal dose density multiplied by the treated area.\n-   Required output: Total emollient mass for one week, in grams, rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded in dermatology and pharmacology. Asteatotic dermatitis is a clinical condition, and its treatment with emollients, along with concepts like transepidermal water loss (TEWL), body surface area (BSA), and dose density, are standard in the field. The provided values are clinically realistic. The problem is well-posed, providing all necessary information for a unique solution. The language is objective and precise. The assumptions (e.g., no loss) are standard simplifications for such a calculation problem. There are no contradictions, ambiguities, or logical fallacies. The problem is therefore deemed valid.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Solution Derivation**\nThe objective is to calculate the total mass of emollient, $M_{total}$, required for a treatment course of one week.\n\nLet the given variables be denoted as follows:\n-   Areal dose density: $\\sigma = 2\\,\\mathrm{g}/\\mathrm{m}^{2}$\n-   Body surface area: $A = 1.7\\,\\mathrm{m}^{2}$\n-   Application frequency: $f = 4\\,\\mathrm{day}^{-1}$\n-   Treatment duration: $T = 7\\,\\mathrm{days}$\n\nThe problem states that the mass applied per application, which we denote as $m_{app}$, is the product of the areal dose density and the treated area. In this case, the treated area is the full body surface area.\n$$m_{app} = \\sigma \\times A$$\n\nSubstituting the given values:\n$$m_{app} = (2\\,\\mathrm{g}/\\mathrm{m}^{2}) \\times (1.7\\,\\mathrm{m}^{2}) = 3.4\\,\\mathrm{g}$$\nThis is the mass of emollient used for a single application.\n\nThe regimen requires applications $f$ times per day. Therefore, the total mass of emollient required per day, $m_{day}$, is the mass per application multiplied by the frequency of applications per day.\n$$m_{day} = m_{app} \\times f$$\n\nSubstituting the value of $m_{app}$ and the given frequency $f$:\n$$m_{day} = (3.4\\,\\mathrm{g}) \\times (4\\,\\mathrm{day}^{-1}) = 13.6\\,\\mathrm{g/day}$$\n\nThe treatment is prescribed for a duration of $T$ days. The total mass of emollient required for the entire duration, $M_{total}$, is the mass per day multiplied by the number of days in the treatment period.\n$$M_{total} = m_{day} \\times T$$\n\nSubstituting the value of $m_{day}$ and the given duration $T$:\n$$M_{total} = (13.6\\,\\mathrm{g/day}) \\times (7\\,\\mathrm{days}) = 95.2\\,\\mathrm{g}$$\n\nThe problem requires the final answer to be expressed in grams and rounded to three significant figures. The calculated value, $95.2\\,\\mathrm{g}$, is already expressed to three significant figures. Therefore, no further rounding is necessary.\n\nThe entire calculation can be combined into a single expression:\n$$M_{total} = \\sigma \\times A \\times f \\times T$$\n$$M_{total} = (2\\,\\mathrm{g}/\\mathrm{m}^{2}) \\times (1.7\\,\\mathrm{m}^{2}) \\times (4\\,\\mathrm{day}^{-1}) \\times (7\\,\\mathrm{days})$$\n$$M_{total} = 95.2\\,\\mathrm{g}$$", "answer": "$$\\boxed{95.2}$$", "id": "4413712"}, {"introduction": "For inflammatory flares of asteatotic dermatitis, topical corticosteroids are a primary adjunctive therapy to control pruritus and eczematous changes. However, their use requires careful management to avoid local and systemic side effects. This exercise provides a practical application of the Fingertip Unit (FTU) system to quantify the total cumulative dose of an active corticosteroid over a month-long tapering regimen, reinforcing the importance of precise dosing and monitoring total drug exposure in clinical practice [@problem_id:4413750].", "problem": "A $68$-year-old patient with asteatotic dermatitis (eczema craquelé) predominantly involving both lower legs is prescribed a mid-potency topical corticosteroid cream for an anti-inflammatory induction-and-taper regimen integrated with liberal emollient use. The corticosteroid cream is mometasone furoate $0.1\\%$ by mass. The dosing is standardized by the Fingertip Unit (FTU), where one Fingertip Unit (FTU) is defined as the ribbon of cream expressed from a standard adult tube nozzle of diameter approximately $5$ $\\mathrm{mm}$ extending from the distal interphalangeal crease to the tip of the adult index finger; for adults, one FTU is commonly observed to have a mass of approximately $0.5$ $\\mathrm{g}$ when expressed from a standard tube.\n\nIt is a well-tested clinical dosing fact that, for adults, one lower leg (excluding the foot) typically requires approximately $4$ FTUs to deliver a thin, evenly spread layer of topical corticosteroid. The treatment plan is:\n- From day $1$ through day $14$ (inclusive), the patient applies the corticosteroid once daily to both lower legs.\n- From day $15$ through day $30$ (inclusive), the patient applies the corticosteroid on alternate days, beginning on day $15$, to both lower legs.\n\nAdherence over the month is imperfect; assume the fraction of scheduled applications actually performed is $0.88$. Assume the FTU-to-mass relationship remains constant throughout and ignore any variation due to tube nozzle differences or formulation density.\n\nStarting from the FTU definition and the concentration of active drug, compute the expected cumulative mass of active corticosteroid applied over the entire $30$-day period. Express your final answer in grams and round to four significant figures.", "solution": "The user-provided problem is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\n- Corticosteroid cream concentration, $C$: mometasone furoate $0.1\\%$ by mass.\n- Fingertip Unit (FTU) mass, $m_{\\text{FTU}}$: approximately $0.5 \\, \\mathrm{g}$.\n- Coverage requirement per lower leg, $N_{\\text{FTU/leg}}$: approximately $4$ FTUs.\n- Application area: Both lower legs ($2$ legs).\n- Treatment period: $30$ days.\n- Dosing schedule, Phase 1 (days $1$ through $14$): Once daily.\n- Dosing schedule, Phase 2 (days $15$ through $30$): Alternate days, beginning on day $15$.\n- Adherence rate, $A$: $0.88$.\n- Requested output: Total cumulative mass of active corticosteroid in grams, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, drawing on established concepts in clinical dermatology and pharmacology, such as the use of mometasone furoate for dermatitis, the induction-and-taper regimen, and the Fingertip Unit (FTU) for dosing. The scenario is realistic, and all numerical values ($0.1\\%$ concentration, $0.5 \\, \\mathrm{g}$ per FTU, $4$ FTUs per leg) are standard clinical approximations. The problem is well-posed, providing all necessary data for a unique solution without internal contradictions. The language is objective and precise.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A quantitative solution can be derived.\n\n### Solution Derivation\n\nThe objective is to compute the total mass of the active drug component, mometasone furoate, applied over a $30$-day period. This is accomplished by first determining the total mass of the cream applied and then multiplying by the drug's mass concentration.\n\n1.  **Mass of cream per application:**\n    The cream is applied to both lower legs. The number of FTUs required for one lower leg is given as $N_{\\text{FTU/leg}} = 4$. Therefore, a single application covering both legs requires a total number of FTUs, $N_{\\text{FTU/app}}$, calculated as:\n    $$N_{\\text{FTU/app}} = 2 \\, (\\text{legs}) \\times 4 \\, \\frac{\\text{FTU}}{\\text{leg}} = 8 \\, \\text{FTUs}$$\n    The mass of one FTU is given as $m_{\\text{FTU}} = 0.5 \\, \\mathrm{g}$. The mass of cream per application, $M_{\\text{app}}$, is:\n    $$M_{\\text{app}} = N_{\\text{FTU/app}} \\times m_{\\text{FTU}} = 8 \\times 0.5 \\, \\mathrm{g} = 4.0 \\, \\mathrm{g}$$\n\n2.  **Total number of scheduled applications:**\n    The treatment regimen is divided into two phases.\n    -   **Phase 1:** From day $1$ through day $14$ (inclusive), the application is once daily. The number of days is $14 - 1 + 1 = 14$. The number of scheduled applications in this phase, $n_1$, is:\n        $$n_1 = 14$$\n    -   **Phase 2:** From day $15$ through day $30$ (inclusive), the application is on alternate days, starting on day $15$. The days of application are $15, 17, 19, 21, 23, 25, 27, 29$. The number of scheduled applications in this phase, $n_2$, is the count of these days, which is $8$:\n        $$n_2 = 8$$\n    The total number of scheduled applications, $N_{\\text{sched}}$, is the sum of applications from both phases:\n    $$N_{\\text{sched}} = n_1 + n_2 = 14 + 8 = 22$$\n\n3.  **Actual number of applications:**\n    The patient's adherence is imperfect, with a given adherence rate of $A = 0.88$. The actual number of applications performed, $N_{\\text{actual}}$, is:\n    $$N_{\\text{actual}} = N_{\\text{sched}} \\times A = 22 \\times 0.88 = 19.36$$\n\n4.  **Total mass of cream applied:**\n    The total mass of cream applied, $M_{\\text{total\\_cream}}$, is the product of the actual number of applications and the mass of cream per application:\n    $$M_{\\text{total\\_cream}} = N_{\\text{actual}} \\times M_{\\text{app}} = 19.36 \\times 4.0 \\, \\mathrm{g} = 77.44 \\, \\mathrm{g}$$\n\n5.  **Total mass of active corticosteroid:**\n    The cream contains mometasone furoate at a concentration of $C = 0.1\\%$ by mass, which is equivalent to a mass fraction of $0.001$. The total mass of the active corticosteroid, $M_{\\text{active}}$, is:\n    $$M_{\\text{active}} = M_{\\text{total\\_cream}} \\times C = 77.44 \\, \\mathrm{g} \\times 0.001 = 0.07744 \\, \\mathrm{g}$$\n\n6.  **Final Answer Formatting:**\n    The problem requires the answer to be in grams and rounded to four significant figures. The calculated value, $0.07744 \\, \\mathrm{g}$, has exactly four significant figures (the digits $7, 7, 4, 4$). Therefore, no additional rounding is required.", "answer": "$$\\boxed{0.07744}$$", "id": "4413750"}]}